{"entity":{"id":"filamon","kind":"company","name":"Filamon","aka":["Filamon Ltd"],"tldr":"Filamon, an Australian company working on long-term inflammatory diseases of ageing, is testing a new type of drug in solid tumours that aims to stop cancer cells changing into a form that spreads.","summary":"Filamon Ltd (ACN 630 721 783), based in Hawthorn East, Melbourne, develops drugs aimed at what it calls master switches of chronic inflammation, across cancer, fibrotic disease, eye disease and other age-related conditions. In oncology, KESONOTIDE and ALPHA-D3 are described by the company as a new class of chemotherapy acting through EGFR degradation and vimentin inhibition to block the epithelial-mesenchymal transition. KESONOTIDE, which the registry calls a novel hGIIA-vimentin inhibitor, is in an adaptive phase 1/2 study in solid tumours including prostate and breast cancer (NCT06926075). Its first registered cancer trial, NCT06926075, was posted on ClinicalTrials.gov in April 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://filamon.com/"},{"label":"KESONOTIDE and ALPHA-D3","url":"https://filamon.com/our-pipeline/kesonotide/"}],"tags":[],"related":[],"cancers":["prostate","breast-cancer"],"sections":["chemotherapy"],"technologies":["cytotoxic-chemotherapy"],"targets":["egfr"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06926075"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company overview, KESONOTIDE page and Hawthorn East address read on the company website on 29 October 2026. Founding year not stated on the pages read. No financing round was read. Cancer is one of several disease areas for this company, which was kept because its registered trial is a cancer study of its own drug; the chemotherapy technology tag follows the company's own description and the EGFR relation reflects its stated mechanism, neither independently confirmed."],"hq":"Melbourne","country":"AU","companyType":"biotech","website":"https://filamon.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/filamon/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"trial":[{"id":"nct06926075","kind":"trial","name":"Early Phase Study of KESONOTIDE™in Participants With Solid Tumours","route":"/trials/nct06926075/"}]}}